Testing citrate fluid safety during kidney filtration (CRRT)
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 study checks whether Prismocitrate 18 is safe for adults who need a kidney filtration treatment called CRRT. It is mainly for people who cannot safely use heparin (a common blood thinner) due to bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Be a candidate for CRRT (a machine-based kidney filtration treatment)
- Be expected to live at least 24 hours
- Have a reason you can’t use heparin safely, or you have a higher bleeding risk
- Have signed consent (you or your legal decision-maker)
- Not be allergic to citrate or have had citrate toxicity or related reactions before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a specific blood-thinning method using citrate works safely and effectively in critically ill patients whose kidneys have suddenly stopped working and need a special filtering machine. Researchers want to confirm that this approach prevents dangerous blood clots while keeping patients safe.
This study tests different doses of a continuous blood-filtering treatment for critically ill patients with sudden kidney failure. It may help doctors find the best dose to improve outcomes.
This trial tests two different blood-thinning methods used during continuous kidney-support treatment (CRRT) for patients who have developed severe kidney injury due to sepsis. The goal is to see which method works better and is safer for patients in this critical condition.
This trial looks at how a type of continuous kidney dialysis, called CRRT, works in very sick patients in the intensive care unit. It may help doctors learn more about how to best care for people who need this treatment.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
This trial tests a customized approach to preventing blood clots during continuous kidney dialysis (CRRT) in patients whose bodies have trouble processing citrate, often due to liver problems or severe illness. The goal is to find the right citrate dose for each patient to keep the dialysis running safely.
Hear when a new Continuous Renal Replacement Therapy (CRRT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.